NDRAHealthcare · Diagnostics & ResearchNDRA Stock Forecast: ENDRA Life Sciences, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering ENDRA Life Sciences, Inc. hold a median 12-month price target of $25 — +498.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 1 Aug 2026 — in the upper half.
NDRA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores ENDRA Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own ENDRA Life Sciences, Inc. — and when they’d sell — is the membership.
NDRA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NDRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +498.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 June 2026 | Ascendiant Capital | Maintains | Buy | $27 → $25 |
| 8 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 30 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 7 June 2024 | Ascendiant Capital | Maintains | Buy | — |
| 31 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Apr 2022 | HC Wainwright & Co. | Maintains | Buy | $6.00 → $5.00 |
| 15 July 2019 | H.C. Wainwright | Initiates | Buy | — |
| 15 July 2019 | HC Wainwright & Co. | Initiates | Buy | — |
| 20 May 2019 | Lake Street | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NDRA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
ENDRA Life Sciences, Inc. (NDRA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.2×
- Price / sales
- —
- Price / book
- 2.9×
- EV / EBITDA
- −0.9×
Cheaper than 72% of US stocks
Cheaper than 34% of US stocks
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −412.6%
- Return on assets
- −122.3%
- Dividend yield
- —
Higher than 3% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
NDRA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NDRA appears on the weeks it earns a place.
Frequently asked questions about NDRA stock
What is the NDRA stock price forecast for 2026-2027?
The 1 Wall Street analysts covering ENDRA Life Sciences, Inc. have a median 12-month price target of $25, with estimates ranging from $25 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NDRA stock a buy right now?
Of the 1 analysts covering ENDRA Life Sciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ENDRA Life Sciences, Inc. 55 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NDRA?
As at 1 Aug 2026, ENDRA Life Sciences, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
Will NDRA stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +498.1% from the last close, and Ticker Nerd's factor model ranks ENDRA Life Sciences, Inc. 55 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NDRA stock forecast for 2030?
No analyst covering ENDRA Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NDRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $25 over the next 12 months.
How has NDRA stock performed over the past year?
ENDRA Life Sciences, Inc. returned -13.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ENDRA Life Sciences, Inc. do?
Endra Life Sciences Inc. is a health technology company dedicated to developing meaningful innovations in the medical imaging sector.
About ENDRA Life Sciences, Inc.
Endra Life Sciences Inc. is a health technology company dedicated to developing meaningful innovations in the medical imaging sector. The company's primary focus is the advancement and commercialization of its proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS) platform, which aims to provide more effective imaging compared to traditional ultrasound. Endra seeks to improve early diagnosis and treatment monitoring by offering clinicians additional insights into liver fat quantification—an essential factor in detecting and managing non-alcoholic fatty liver disease (NAFLD). Operating in the global healthcare industry, Endra Life Sciences addresses significant diagnostic challenges by integrating cutting-edge technology into routine medical practices. The TAEUS platform stands out for its ability to enhance existing ultrasound systems, thereby facilitating cost-effective and non-invasive assessments of metabolic diseases. Endra Life Sciences plays a pivotal role in the ongoing shift towards more precise and accessible healthcare solutions. By bridging the gap between advanced imaging and everyday clinical use, the company contributes to the broader efforts of improving patient outcomes and reducing healthcare costs.
CEO Mr. Alexander Y. Tokman · 9 employees · United States · https://endrainc.com